Company intelligence / Profile preview
Marker Therapeutics, Inc.
Houston, Texas, United Statesmarkertherapeutics.com ↗
- Ownership
- Public · MRKR
- Development stage
- Phase 1
01
Overview
MT-601 in lymphoma patients showed 78% objective response rate with 44.4% complete responses in first dose cohort. The therapy demonstrated good safety with no ICANS and only one case of Grade 1 cytokine release syndrome. MT-401 showed clinical benefits in AML patients with measurable residual disease.
- Therapeutic areas
- Oncology
- Modalities
- T cell-based immunotherapiesMulti-Antigen Recognizing T cell (MAR-T cell) therapy
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
Request access →03
Partnerships
Baylor College of Medicine
04
Financials
- Market cap
- $20.2M
- Total revenue
- $0
- Enterprise value
- $8.8M
Beyond the preview
Go deeper on Marker Therapeutics, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Marker Therapeutics, Inc..